Zarix Thymitaq
Executive Summary
Firm plans to begin Phase III studies of nolatraxed for treatment of unresectable hepatocellular carcinoma as early as September following receipt of "Fast Track" designation from FDA. The company expects the trials to last through 2002, with a U.S. NDA filing possible by the end of 2002. Zarix licensed Thymitaq from Agouron in 1998 (1"The Pink Sheet" Jan. 18, 1998, p. 24)